Skip Navigation


Carcinogenesis Advance Access originally published online on March 6, 2007
Carcinogenesis 2007 28(7):1463-1470; doi:10.1093/carcin/bgm042
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/7/1463    most recent
bgm042v2
bgm042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Agarwal, C.
Right arrow Articles by Agarwal, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agarwal, C.
Right arrow Articles by Agarwal, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells

Chapla Agarwal1,2, Alpna Tyagi1, Manjinder Kaur1 and Rajesh Agarwal1,2,*

1 Department of Pharmaceutical Sciences, School of Pharmacy
2 University of Colorado Cancer Center, University of Colorado Health Sciences Center, 4200 East 9th Avenue, PO Box C238, Denver, CO 80262, USA

* To whom correspondence should be addressed. Tel: +303 315 1381, Fax: +303 315 6281; Email: rajesh.agarwal{at}uchsc.edu

Transcription factor signal transducer and activator of transcription (Stat)-3 is activated constitutively in prostate cancer (PCA) suggesting that its disruption could be an effective approach to control this malignancy. Here we assessed whether silibinin, a flavanone from Silybum marianum with proven anticancer efficacy in various cancer models, inhibits Stat3 activation in DU145 cells, and if it does, what is the biological fate of the cells? At 50 µM or higher concentrations for 24 or 48 h, silibinin concentration dependently reduced constitutive Stat3 phosphorylation at Tyr705 and Ser727 residues under both serum and serum-starved conditions. Constitutively active Stat3–DNA binding was also inhibited concentration dependently by silibinin; however, apoptotic death together with caspase and poly(ADP-ribose) polymerase (PARP) cleavage was observed by silibinin only under serum-starved conditions suggesting that additional survival pathways are active under serum conditions. In other studies, cells were treated with various specific pharmacological inhibitors where phosphorylation of Stat3 was not reduced by epidermal growth factor receptor and Mitogen activated protein/extracellular signal regulate kinase kinase (MEK1/2) inhibitors, suggesting lack of significant roles of these in Stat3 activation in DU145 cells. Janus kinase (JAK)-1 and JAK2 inhibitors strongly reduced Stat3 phosphorylation but did not result in apoptotic cell death. Interestingly, JAK1 inhibitor only in combination with silibinin resulted in a complete reduction in Stat3 phosphorylation at Tyr705, activated caspase-9 and caspase-3, and caused strong PARP cleavage and apoptotic death of DU145 cells. Given a critical role of Stat3 activation in PCA, our results showed that silibinin inhibits constitutively active Stat3 and induces apoptosis in DU145 cells, and thus might have potential significance in therapeutic intervention of this deadly malignancy.

Abbreviations: EGFR, epidermal growth factor receptor; ELISA, enzyme-linked immunosorbent assay; EMSA, electrophoretic mobility shift assay; JAK, Janus kinase; PARP, poly(ADP-ribose) polymerase; PCA, prostate cancer; Stat, signal transducer and activator of transcription

Received January 5, 2007; revised February 13, 2007; accepted February 16, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
P.-L. Kuo, W.-C. Ni, E.-M. Tsai, and Y.-L. Hsu
Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells
Mol. Cancer Ther., May 1, 2009; 8(5): 1328 - 1339.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. P. Sahu and S. K. Srivastava
The Role of STAT-3 in the Induction of Apoptosis in Pancreatic Cancer Cells by Benzyl Isothiocyanate
J Natl Cancer Inst, February 4, 2009; 101(3): 176 - 193.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. P. Singh, K. Raina, G. Deep, D. Chan, and R. Agarwal
Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3 Orthotopic Xenograft via Activation of Extracellular Signal-Regulated Kinase 1/2 and Inhibition of Signal Transducers and Activators of Transcription Signaling
Clin. Cancer Res., January 15, 2009; 15(2): 613 - 621.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D.-S. Shin, H.-N. Kim, K. D. Shin, Y. J. Yoon, S.-J. Kim, D. C. Han, and B.-M. Kwon
Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells
Cancer Res., January 1, 2009; 69(1): 193 - 202.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
B. Velmurugan, R. P. Singh, A. Tyagi, and R. Agarwal
Inhibition of Azoxymethane-Induced Colonic Aberrant Crypt Foci Formation by Silibinin in Male Fisher 344 Rats
Cancer Prevention Research, October 1, 2008; 1(5): 376 - 384.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.